List of Excipients in Branded Drug CADUET

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pfizer Laboratories Div Pfizer Inc	CADUET	amlodipine besylate and atorvastatin calcium	0069-2150	CALCIUM CARBONATE
Pfizer Laboratories Div Pfizer Inc	CADUET	amlodipine besylate and atorvastatin calcium	0069-2150	CELLULOSE, MICROCRYSTALLINE
Pfizer Laboratories Div Pfizer Inc	CADUET	amlodipine besylate and atorvastatin calcium	0069-2150	CROSCARMELLOSE SODIUM
Pfizer Laboratories Div Pfizer Inc	CADUET	amlodipine besylate and atorvastatin calcium	0069-2150	HYDROXYPROPYL CELLULOSE
Pfizer Laboratories Div Pfizer Inc	CADUET	amlodipine besylate and atorvastatin calcium	0069-2150	MAGNESIUM STEARATE
Pfizer Laboratories Div Pfizer Inc	CADUET	amlodipine besylate and atorvastatin calcium	0069-2150	POLYETHYLENE GLYCOL 3000
Pfizer Laboratories Div Pfizer Inc	CADUET	amlodipine besylate and atorvastatin calcium	0069-2150	POLYSORBATE 80

CADUET Excipient Strategy and Commercial Opportunities: Formulation, Generic Entry, and Patent Analysis

Last updated: August 9, 2026

Caduet is a fixed-dose oral tablet combining amlodipine besylate, a calcium-channel blocker, with atorvastatin calcium, an HMG-CoA reductase inhibitor. Its commercial value is based on adherence, cardiovascular risk reduction, and treatment consolidation rather than a novel delivery system. The principal formulation opportunities are lower-cost generic manufacture, improved swallowability, excipient simplification, stability control, and alternative combination presentations.

Caduet is exposed to conventional generic competition because its active ingredients are small molecules, its dosage form is an immediate-release tablet, and its core product patents and regulatory exclusivities have expired. The strongest commercial strategy is an ANDA or non-U.S. generic program supported by robust control of atorvastatin degradation, tablet mechanical performance, dissolution, and excipient compatibility.

What is Caduet and which active ingredients does it contain?

Caduet contains amlodipine besylate and atorvastatin calcium in fixed dose combinations approved for hypertension, coronary artery disease, and hyperlipidemia management. The product is available in multiple strength combinations, including amlodipine doses of 5 mg or 10 mg and atorvastatin doses ranging from 10 mg to 80 mg, depending on the marketed presentation and jurisdiction.

Product attribute	Caduet profile
Brand	Caduet
Active ingredients	Amlodipine besylate and atorvastatin calcium
Drug classes	Dihydropyridine calcium-channel blocker and statin
Dosage form	Immediate-release film-coated tablet
Route	Oral
Original sponsor	Pfizer
FDA product type	Fixed-dose combination drug
Primary commercial rationale	Hypertension or coronary disease treatment combined with lipid lowering
Generic pathway	ANDA in the United States, subject to product-specific requirements
Biologic risk	None; Caduet is not a biologic

The combination is pharmacologically logical because hypertension and dyslipidemia frequently coexist. A fixed-dose tablet can reduce pill burden, but the combination also creates a dose-selection constraint. Patients may require titration of amlodipine and atorvastatin independently, limiting the addressable market compared with separate tablets.

What excipients are used in Caduet tablets?

Caduet uses conventional immediate-release tablet excipients. Public product information identifies calcium carbonate, microcrystalline cellulose, croscarmellose sodium, polysorbate 80, hydroxypropyl cellulose, and magnesium stearate among the inactive ingredients. The film coating contains standard coating materials, including hypromellose-based coating components and colorants, depending on strength and market presentation. The FDA-approved labeling should control any final product-specific excipient assessment. [1]

Excipient	Likely formulation function	Commercial relevance
Calcium carbonate	Diluent and alkalizing or microenvironment-modifying agent	May support stability and tablet mass; requires control of mineral variability
Microcrystalline cellulose	Filler and dry-binder	Supports compactibility and direct compression
Croscarmellose sodium	Superdisintegrant	Controls tablet breakup and dissolution
Hydroxypropyl cellulose	Binder	Supports granule or tablet cohesion
Polysorbate 80	Wetting or solubilizing aid	Can improve dispersion but requires oxidation and peroxide control
Magnesium stearate	Lubricant	Excessive use can slow wetting and dissolution
Film-coating polymers	Protection, appearance, swallowability	Creates opportunities for coating-cost and performance optimization
Titanium dioxide or other colorants	Opacity and product identification	Subject to jurisdiction-specific regulatory and market restrictions

The excipient system is not the principal source of Caduet’s exclusivity. Its value lies in reproducible release, manufacturability, and stability. A generic sponsor does not need to copy every inactive ingredient, but it must demonstrate pharmaceutical equivalence and bioequivalence and comply with FDA quality requirements.

How does Caduet’s excipient strategy address formulation challenges?

The formulation must manage two chemically different active ingredients in one immediate-release tablet. Amlodipine is used at a low dose relative to atorvastatin, which creates content-uniformity and segregation risks. Atorvastatin is present at substantially higher strengths and is sensitive to degradation pathways involving oxidation, light, moisture, heat, and potentially acidic or reactive formulation environments.

Calcium carbonate can provide tablet bulk and influence the local microenvironment. Microcrystalline cellulose and hydroxypropyl cellulose provide compactibility and strength. Croscarmellose sodium is important because excessive compression, excessive lubrication, or a dense film coat can delay disintegration.

Polysorbate 80 may improve wetting and dispersion, but it can carry peroxide impurities that create compatibility concerns for oxidation-sensitive drug substances. The excipient should be sourced under tight peroxide, water, and microbial specifications. Magnesium stearate levels and blending time also require control because over-lubrication can reduce wettability and alter dissolution.

A development program should evaluate:

1. Amlodipine content uniformity at the lowest drug load.
2. Atorvastatin assay and degradation products across the full strength range.
3. Dissolution in discriminatory media.
4. Blend uniformity and segregation during scale-up.
5. Tablet hardness, friability, disintegration, and coating integrity.
6. Stability under long-term and accelerated conditions.
7. Extractables and leachables from packaging.
8. Excipient variability across commercial suppliers.

What formulations are protected by Caduet’s product and formulation history?

Caduet’s principal dosage form is an immediate-release combination tablet. The commercial formulation is protected primarily through regulatory approval, product-specific labeling, manufacturing know-how, and historical patent coverage rather than through a currently active broad formulation monopoly.

The main protection categories are:

Protection category	Relevance to Caduet
Active-ingredient patents	Historically covered amlodipine and atorvastatin separately, not necessarily the combination
Fixed-dose combination patents	Could cover combining the two agents or specific dose ratios
Formulation patents	May cover excipient selection, solid-state properties, stability, or manufacturing steps
Method-of-use patents	Could cover treatment of combined cardiovascular conditions, subject to claim scope and enforceability
Regulatory exclusivity	Expired for the original small-molecule approval
Trade secrets	Process parameters, coating conditions, supplier controls, and analytical methods remain commercially relevant

A generic sponsor should conduct a current patent and regulatory review rather than assume that all historical Caduet-related patents are expired. The relevant questions include whether any unexpired U.S. patent is listed in the Orange Book, whether a patent covers a specific strength or indication, and whether the proposed label can omit a protected use through a section viii statement.

When did Caduet lose exclusivity?

Caduet’s exclusivity has expired in the United States. The product was approved in 2004, and the small-molecule regulatory exclusivity period has long ended. The underlying patents associated with amlodipine, atorvastatin, and the fixed-dose combination have also passed their principal commercial protection periods.

The commercial consequence is that generic manufacturers can pursue immediate-release amlodipine/atorvastatin tablets through the ANDA pathway, provided they satisfy FDA requirements for pharmaceutical equivalence, bioequivalence, chemistry, manufacturing, and controls. The exact date of commercial generic entry depends on the approved ANDA, patent certifications, litigation outcomes, and any authorized-generic arrangements.

What is the Orange Book status of Caduet?

The Orange Book is the key U.S. reference for approved drug products, therapeutic equivalence evaluations, and listed patents. Caduet should be reviewed by strength and application because listing status can change across editions and because patents may attach to specific products or uses.

A current Orange Book review should assess:

• Listed patents for the relevant Caduet reference-listed drug.
• Patent expiration dates and any pediatric extension.
• Whether patents are method-of-use patents.
• Whether patents have been delisted or expired.
• Therapeutic-equivalence ratings for approved amlodipine/atorvastatin products.
• Whether a proposed generic has an AB rating for each relevant strength.

FDA’s Orange Book does not itself determine the full scope of freedom to operate. Patent claims not listed in the Orange Book may still affect manufacturing, use, packaging, or commercial practices. [2]

Which companies are challenging Caduet with generic products?

Caduet has been subject to generic competition from manufacturers of amlodipine besylate and atorvastatin calcium combination tablets. Generic participation in this category can include large multinational manufacturers, specialty generic companies, and regional suppliers that obtain approval through ANDAs or equivalent non-U.S. pathways.

The competitive landscape is driven by:

• Number of approved suppliers by strength.
• Availability of all dose combinations.
• Therapeutic-equivalence ratings.
• Manufacturing cost and tablet yield.
• Wholesale acquisition price and payer reimbursement.
• Ability to supply multiple markets.
• FDA inspection history and supply reliability.
• Contracting relationships with wholesalers and health plans.

The most commercially attractive strengths are not necessarily the highest atorvastatin doses. Low-dose atorvastatin combinations may have greater volume, while 10 mg amlodipine/80 mg atorvastatin may have higher active pharmaceutical ingredient cost and lower patient volume.

What generic entry risks exist for Caduet?

Generic entry risk is high because the product is an immediate-release small-molecule combination with established reference-product data. The main risks are technical and commercial rather than fundamental patent barriers.

Bioequivalence risk

The sponsor must demonstrate bioequivalence for both active ingredients. A formulation that improves release of one active ingredient but changes exposure to the other may fail the comparative pharmacokinetic assessment. The lowest-strength amlodipine component can create analytical sensitivity and content-uniformity problems.

Dissolution risk

The generic should match or appropriately compare with the reference product across multiple dissolution conditions. Calcium carbonate, magnesium stearate, croscarmellose sodium, and coating thickness can materially affect wetting and release.

Stability risk

Atorvastatin degradation is a central development concern. Stability programs should monitor known and potential degradation products, including oxidation-related impurities and lactone-related species where relevant to the drug substance and product conditions. Packaging selection is part of the formulation strategy, not a later commercial decision.

Manufacturing risk

Direct compression may reduce cost, but it can increase segregation risk where one active is present at a low dose. Wet granulation or separate premixing may improve uniformity but increase processing complexity and stability exposure.

Commercial risk

A crowded generic market can compress pricing rapidly. A sponsor with only one or two strengths may have limited value to wholesalers and institutional buyers. Broad strength coverage and dependable supply are more valuable than marginal excipient savings.

What excipient opportunities exist for Caduet generics?

Excipient simplification

A generic developer may reduce the number of excipients if it can maintain dissolution, content uniformity, stability, and tablet performance. Simplification can lower procurement cost and reduce supplier qualification burden. The risk is that removing calcium carbonate, polysorbate 80, or a binder may destabilize the product or impair release.

Direct-compression platforms

Microcrystalline cellulose, a suitable disintegrant, and controlled lubrication can support direct compression. This approach has a lower equipment burden and shorter process cycle. It is most attractive when blend uniformity can be demonstrated across all strengths.

Separate granulation or premix strategy

Amlodipine may require a controlled premix because of its low concentration. A separate active-premix step can reduce segregation and improve content uniformity. The additional operation increases cost but may improve regulatory robustness.

Coating optimization

A thinner or faster coating can reduce coating-material consumption and cycle time. The coating must still protect the tablet, support identification, and avoid altering dissolution. A color-coded strength strategy can reduce medication errors but may increase inventory complexity.

Excipient substitution

Potential substitution areas include:

• Alternative cellulose grades.
• Low-peroxide surfactant sources or replacement of polysorbate 80.
• Alternative superdisintegrants.
• Lower-variability calcium carbonate grades.
• Hypromellose-based coatings with reduced pigment load.
• Low-moisture excipient systems for improved atorvastatin stability.

Each substitution requires comparative dissolution, stability, impurity, and bioequivalence assessment. A change that is acceptable in one strength may not perform equivalently across the full product family.

How strong is the patent estate for Caduet?

The current patent estate is commercially weak relative to a newly launched combination product. Caduet has no biologic exclusivity, no biosimilar barrier, and no obvious continuing market exclusivity based solely on its historical brand status. The practical barriers are formulation development, regulatory execution, supply reliability, and pricing.

Patent strength can still arise from narrow claims covering:

• Specific crystalline forms or salts.
• Stabilized atorvastatin compositions.
• Defined excipient ratios.
• Manufacturing processes.
• Packaging systems.
• New dosage forms or modified-release combinations.

Such claims would need to be assessed claim by claim. A generic tablet that uses different excipients and a non-infringing process may avoid a narrow formulation patent while remaining pharmaceutically equivalent.

What licensing and partnering opportunities exist for Caduet?

Licensing opportunities are more likely to involve manufacturing capability than control of core Caduet intellectual property. Potential deal structures include:

Opportunity	Potential partner value
ANDA acquisition or out-license	Provides an approved or near-approved U.S. product
Regional commercialization	Gives a local company rights in markets where Pfizer branding remains relevant
Contract manufacturing	Supports low-cost, high-volume tablet production
Excipient platform licensing	Provides stabilized or low-peroxide formulation technology
Coated-tablet technology	Improves throughput, identification, or patient acceptability
Portfolio bundling	Combines Caduet-equivalent tablets with separate amlodipine and statin products
Authorized-generic arrangement	Can preserve brand-linked supply and channel access

A licensing transaction should value the number of approved strengths, the status of regulatory files, manufacturing cost, supply history, and remaining market size. Historical brand recognition alone is unlikely to justify a premium in a mature generic market.

How does Caduet compare with separate amlodipine and atorvastatin products?

Caduet’s main commercial advantage is pill-burden reduction. Separate products provide superior titration flexibility and may be cheaper after generic substitution. The fixed-dose combination is most defensible where patients are stable on both ingredients and adherence is a major treatment objective.

Factor	Caduet-equivalent combination	Separate generic tablets
Pill burden	Lower	Higher
Dose flexibility	Lower	Higher
Manufacturing complexity	Higher	Lower per product
Patient switching	Requires matched combination	Easier independent titration
Generic price pressure	High	High
Adherence proposition	Stronger	Depends on regimen
Formulation risk	Two active ingredients in one tablet	One active ingredient per tablet
Commercial differentiation	Combination convenience	Broad dose and supplier flexibility

The opportunity is strongest in payer systems that reimburse fixed-dose combinations, in cardiovascular portfolios that already include both APIs, and in markets with adherence-focused prescribing.

Key Takeaways

• Caduet combines amlodipine besylate and atorvastatin calcium in an immediate-release film-coated tablet.
• Its excipient strategy relies on conventional diluents, binders, disintegrants, lubricants, wetting agents, and coating materials.
• The central formulation risks are amlodipine content uniformity, atorvastatin degradation, dissolution control, and excipient compatibility.
• U.S. regulatory exclusivity and core commercial patent protection have expired, making generic entry commercially feasible.
• The strongest generic opportunities are broad strength coverage, reliable supply, excipient simplification, packaging optimization, and adherence-focused commercialization.
• Patent barriers are likely to be narrow and claim-specific rather than broad product monopolies.
• Caduet has no biosimilar risk because it is a small-molecule drug.
• Separate amlodipine and atorvastatin products compete directly through lower cost and greater dose flexibility.
• Commercial value depends more on manufacturing economics, payer access, and supply reliability than on brand-derived pricing power.

FAQs

Can a generic Caduet tablet use different excipients?

Yes. An ANDA applicant generally may use different inactive ingredients if the product meets applicable pharmaceutical-equivalence, bioequivalence, quality, labeling, and safety requirements. The substitute excipients must not create unacceptable differences in performance or tolerability.

Is Caduet a combination product eligible for 505(b)(2) approval?

A conventional immediate-release generic equivalent is ordinarily pursued through the ANDA pathway. A materially different dosage form, route, strength, or formulation could require a different regulatory strategy, including a 505(b)(2) application if the statutory and scientific requirements are met.

Does Caduet require a biosimilar development program?

No. Caduet contains small-molecule active ingredients. A biosimilar pathway applies to biological products, not conventional amlodipine/atorvastatin tablets.

Can an excipient change create a new patent opportunity?

Yes, but only if the resulting formulation or process meets patentability requirements. Potential claims could address stability, impurity reduction, dissolution performance, solid-state behavior, or manufacturing efficiency. A routine substitution without unexpected technical results is less likely to support strong patent protection.

What is the most valuable commercial differentiation for a Caduet generic?

The most defensible differentiation is usually dependable multi-strength supply combined with manufacturing cost control and demonstrated stability. Patient-facing differentiation may come from smaller tablets, improved coating, reduced excipient burden, or packaging that supports adherence, provided the product remains bioequivalent and commercially reimbursable.

References

1. Pfizer Inc. (n.d.). Caduet (amlodipine besylate/atorvastatin calcium) prescribing information. U.S. Food and Drug Administration labeling database.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Content and format. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs

4. U.S. Food and Drug Administration. (2016). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

5. U.S. Food and Drug Administration. (2024). Guidance for industry: ANDAs for certain highly soluble, highly permeable, and highly compressible drug products. U.S. Department of Health and Human Services.